PDX Pharmaceuticals has pioneered an innovative therapeutic construct using mesoporous silica nanoparticles (MSNPs) to effectively deliver a combination of potent anti-cancer agents and immune checkpoint inhibitors directly to tumor sites. This approach enhances cancer treatment by simultaneously targeting and killing cancer cells while empowering the immune system to recognize and attack any surviving cells. Key to this breakthrough is the integration of a Programmed Death-Ligand 1 (PD-L1) antibody, which helps “unmask” cancer cells to the immune system, allowing T-cells to eliminate them more effectively.  

The unique MSNPs act as a delivery platform, carrying a customizable blend of drugs, from chemotherapy agents to modern molecular inhibitors. This construct’s modular design allows for flexible drug loading, with cancer-targeting agents, checkpoint inhibitors, and even immune-stimulating adjuvants to heighten efficacy. The potential to reduce drug doses while maintaining or even improving therapeutic effects is a major advantage, as it minimizes systemic side effects. Data from PDX show that their constructs, tested on lung cancer models, achieved similar outcomes at a fraction of typical drug concentrations, showing promise for less toxic cancer therapies.

These nanoparticles can be administered both locally (directly at the tumor site) and systemically, extending their potential to a broad spectrum of cancers, including melanoma, breast cancer, and pancreatic cancer. Beyond killing cancer cells, this approach induces an adaptive immune response that may slow metastatic spread, adding a layer of defense against cancer recurrence. This advanced therapy signifies a substantial leap in cancer treatment, demonstrating PDX Pharmaceuticals’ commitment to developing more precise and immune-focused cancer therapies.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

R&D Tax Credit Preparation Services

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed provides state and federal R&D tax credit preparation and audit services to all 50 states.

If you have any questions or need further assistance, please call or email our CEO, Damian Smyth on (800) 986-4725.
Feel free to book a quick teleconference with one of our national R&D tax credit specialists at a time that is convenient for you.

R&D Tax Credit Audit Advisory Services

creditARMOR is a sophisticated R&D tax credit insurance and AI-driven risk management platform. It mitigates audit exposure by covering defense expenses, including CPA, tax attorney, and specialist consultant fees—delivering robust, compliant support for R&D credit claims. Click here for more information about R&D tax credit management and implementation.

Our Fees

Swanson Reed offers R&D tax credit preparation and audit services at our hourly rates of between $195 – $395 per hour. We are also able offer fixed fees and success fees in special circumstances. Learn more at https://www.swansonreed.com/about-us/research-tax-credit-consulting/our-fees/